Discovering breakthroughs in fibrosis and neurodegeneration

Blade Clinical Trials

Today, we are advancing a robust pipeline of potential first-in-class, oral, small-molecule therapies for diseases that result from protein deposition (fibrosis) or protein aggregation (neurodegeneration) that disrupt normal cellular, tissue or organ function. This pipeline includes an autotaxin inhibitor and multiple inhibitors of dimeric calpains to treat lung, liver and cardiac fibrosis or neurodegenerative diseases.

Find Clinical Trials Near Me

Study Description Study Phase Status Trial number
BLD-0409-101 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Phase 1 Complete NCT04146805
BLD-0409-102 Relative Bioavailability Phase 1 In Process NCT04814472
BLD-0409-103 Drug-Drug Interaction with Probe Substrates for CYP450 Enzymes Phase 1 In Process NCT04814498
BLD-0409-104 Drug-Drug Interaction with Approved Therapies for IPF Phase 1 Planned  
BLD-0409-203 Idiopathic Pulmonary Fibrosis Phase 2 Planned